– USA, MA – Montai Therapeutics, a company pioneering at the intersection of AI, diverse human chemistry, and validated biology to discover breakthrough small molecules for chronic disease, appoints Dr. Larry Hamann (Ph.D.) to its Board of Directors.
About Dr. Larry Hamann
Dr. Hamann is the Co-founder and CEO of Interdict Bio. Previously, he was Global Head of drug Discovery Sciences at Takeda Pharmaceuticals, and before that, Corporate Vice President and Global Head of small Molecule Drug Discovery at Celgene. Before Celgene, Larry held positions of increasing responsibility at Novartis, Bristol-Myers Squibb, and Ligand Pharmaceuticals. In more than 30 years of drug discovery, he has led teams responsible for more than 22 clinical-stage compounds, including several first-in-class therapeutics, and two launched drugs. Further, he is co-inventor on more than 70 patents and co-author of more than 90 scientific publications. Dr. Hamann was awarded the American Chemical Society (ACS) Division of Medicinal Chemistry Award in 2022.
He earned a PhD in Organic Chemistry from the University of Michigan.
About Montai Therapeutics
Montai is pioneering with AI to predictably discover breakthrough small molecule medicines, and precision-matching untapped human chemistry to validate biological pathways to address unmet needs in chronic disease. Montai’s CONECTA platform leverages AI to build a deep network understanding of the connections between human biology and highly diverse Anthromolecule chemistry – curated bioactive molecules with a long history of human consumption in foods, supplements, and herbal medicines. From this precision-matched human co-evolved chemistry, Montai’s generative AI systems unlock access to and rapid optimization of the widest range of high-potential drug candidates, providing unprecedented optionality and predictability in drug development. With an initial focus on inflammatory and autoimmune diseases, Montai is developing a pipeline of accessible, pill-based solutions as biologic replacements and for hard-to-drug targets such as transcription factors. Montai was founded in Flagship Labs in 2019.
For more information: https://www.montai.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.